Back To Search Results


Editor: Preeti Patel Updated: 6/22/2023 10:47:40 AM


Desmopressin (1-deamino-8-D-arginine vasopressin) is a synthetic analog of vasopressin, aka antidiuretic hormone, created in 1977 and used in the treatment of a wide variety of medical conditions including nocturnal polyuria, hemophilia A, diabetes insipidus, Willebrand disease, uremic bleeding, as well as many off label uses such as an adjunct with hypertonic saline to prevent rapid sodium correction, intracranial hemorrhage associated with varying antiplatelet agents, and trauma resuscitation with active hemorrhage.[1][2][3]

Nocturnal polyuria is a commonly encountered condition seen almost exclusively in the pediatric population, which is responsive to both oral and intranasal desmopressin. Desmopressin is also available to adults who awaken more than two times a night to void.[4]

Hemophilia A is an X-linked autosomal recessive disorder characterized by the deficiency or absence of the clotting factor VIII.[5] Factor VIII is an integral component of the intrinsic coagulation pathway, which, when combined with von Willebrand factor, produces the active factor VIIIA, the cofactor responsible for transforming factor X to factor Xa. Factor Xa activates IIa (thrombin) to enable fibrin formation, all of which are integral to the coagulation cascade.[1] As such, a deficiency in factor VIII results in recurrent bleeding, particularly following surgical procedures or extractions.[5] Patients with hemophilia A are also at increased risk of major bleeding secondary to minor injuries, such as hemarthrosis and immediate and/or delayed bleeding following trauma.[5] Desmopressin in the intranasal or intravenous form has FDA approval for use in mild to moderate cases of Hemophilia A, substituted with factor VIII. 

Diabetes insipidus (DI) classically presents with polyuria and polydipsia and can be secondary to multiple other conditions.[6] The two primary types of diabetes inspidus include nephrogenic and central. Nephrogenic diabetes insipidus indicates the inability of the kidneys to respond to antidiuretic hormone or can arise secondary to long-term lithium use or overdose, as well as any multitude of disorders that affect the inherent ability of the kidneys to function optimally.[7][8] Central diabetes insipidus occurs secondary to the inability of the hypothalamus to create ADH and can occur as a result of central neurologic system or head trauma, CNS tumors such as craniopharyngioma, or germinoma, or destruction of ADH by placental enzymes vasopressinase.[9][10][11] In both central and nephrogenic diabetes insipidus, the urine cannot be concentrated optimally with water deprivation, and there is a persistent and continuous excretion of hypotonic urine. Desmopressin administration can be utilized to distinguish between central vs. nephrogenic diabetes insipidus, with a positive response noted in central diabetes insipidus, meaning the kidneys respond appropriately to desmopressin with the expected concentration of the urine and increased reabsorption of fluids, resulting in eutonic urine. 

Uremic platelet dysfunction encompasses multiple pathways and impairments involving uremia, ultimately resulting in platelet dysfunction. While still largely undefined, the most commonly accepted pathogenesis involves platelet dysfunction secondary to impaired platelet adhesiveness, decreased platelet aggregation, and abnormal platelet endothelial interaction. Factors contributing to platelet dysfunction in uremic patients include uremic toxins, anemia, and nitric oxide production. 

Uremic platelet dysfunction occurs for several reasons, including circulating uremic toxins, platelet aggregation inhibition by increased nitric oxide production, and anemia resulting in turbulent rather than a laminar flow of blood products.[12] Desmopressin given intravenously has been shown to improve platelet function within 1 hour of administration.[13]

Von Willebrand disease results from a deficiency in von Willebrand factor. This factor is essential in forming the initial platelet plug as a response to subendothelial tissue exposure.[1] In increasing order of severity, the different types of the disease are Type 1, Type 2B, 2M, and type 3. Indications for desmopressin include the treatment of types 1 and 2M. It is also most effective in treating diseases caused by the variants of Arg1597Gln, Met740Ile, and Tyr1584Cys.[14] Desmopressin has also been found, in observed cases, to decrease the risk of bleeding complications in pregnant patients suffering from a mild to moderate form of the disease with a von Willebrand factor concentration of less than or equal to 20 IU/dL.[15]

In a limited number of studies of patients with subarachnoid hemorrhage, some have demonstrated enough evidence to consider utilizing a single intravenous dose of desmopressin in patients with intracranial hemorrhage pending neurosurgical intervention.[16] 

In a select number of patients suffering from severe hyponatremia with a serum sodium less than 120 mEq/L, studies have demonstrated benefit when utilizing intravenous 3 percent saline while simultaneously initiating desmopressin to prevent rapid correction, decreasing the risk of developing osmotic demyelination syndrome.[17]

Desmopressin has also been utilized in trauma resuscitation and post-surgically to receive hemostasis. Several animal studies have demonstrated that desmopressin is useful in treating severe coagulopathy in injured or post-surgical patients.[16] 

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Desmopressin is a selective vasopressin V2 receptor agonist present throughout the collecting ducts and distal convoluted tubules of the kidneys.[1][18] The V2 receptor is a Gs-protein coupled receptor, which, when activated, results in a signaling cascade of adenyl-cyclase, prompting an increase in cyclic adenosine monophosphate (cAMP) in the renal tubule cells, ultimately resulting in increased water permeability. This activity leads to a decrease in urine volume and an increase in urine osmolality. 

The signaling cascade resulting in the production of cyclic adenosine monophosphate also induces exocytosis of von Willebrand factor and factor VIII from its storage sites, as well as the Weibel-Palade bodies and the alpha granules of platelets.[1] Von Willebrand factor functions as the first step in thrombogenesis, acting as the bridging factor of the Gp1b factor on platelets to the subendothelial collagen following tissue injury.[1] By utilizing synthetic ADH analogs, such as desmopressin, the clotting cascade is facilitated and can result in hemostasis.[19]


Desmopressin can be administered intravenously as a subcutaneous injection, intranasal spray, and, most recently, a dissolvable sublingual strip. Due to the latter's superior bioavailability, the tablet form has been discontinued in many countries in favor of intranasal and sublingual forms.[7] The administration of intravenous and subcutaneous dose forms of the drug are predominantly in the hospital setting. Dosing for both is 0.3 micrograms/kg. Peak blood concentration after intravenous administration occurs within 30 to 60 minutes and after subcutaneous administration within 60 to 90 minutes.[1]

The intranasal form of vasopressin is frequently a choice when administration occurs at home.[20] Each spray typically dispenses 150 micrograms.[1] The intranasal dosage is directly proportional to the patient's weight, with patients weighing less than 50 kg prescribed one spray, or 150 micrograms, and patients over 50 kg prescribed 2 sprays, or 300 micrograms, every 12 to 24 hours. This form of the drug reaches peak levels in 60 to 90 minutes.[1]

Sublingual desmopressin, also known as desmopressin lyophilisate, is administered as a sublingual melt tablet at 120 micrograms.[21] It is generally used in the pediatric population due to the ease of administration and the increased bioavailability.

Adverse Effects

The major adverse effect of desmopressin for which to monitor is hyponatremia. As desmopressin increases the urine concentration, it can also lead to systemic hyponatremia with physiology similar to the syndrome of inappropriate antidiuretic hormone.[22] In certain instances, the hyponatremia caused by this drug can precipitate seizures. The minor adverse effects that may affect individual patients are headaches, tachycardia, and facial flushing. There have been certain instances where patients receiving desmopressin have suffered from strokes or myocardial infarctions. However, these cases were rare and did not establish with certainty that desmopressin exerted a direct influence in these cases.[1]


Hyponatremia is an absolute contraindication to the administration of desmopressin, except for symptomatic hyponatremia warranting aggressive management with the potential for osmotic demyelinating syndrome. Desmopressin acts primarily in the nephron; this drug is contraindicated in patients with renal impairment.[22] Also, renal function decreases with age; therefore, care is necessary when prescribing this drug in the older population. This drug should also be avoided in younger patients, especially those under the age of 2, as it is difficult to restrict water and fluids in such patients.[1] Additionally, this drug is ineffective in patients suffering from type 3 von Willebrand disease; therefore, these patients should not receive the drug.[1] Finally, patients suffering from thrombocytopenic purpura should not receive desmopressin, as it can precipitate a thrombotic event.[1] Lastly, desmopressin is contraindicated in patients with known hypersensitivity to desmopressin acetate.


Desmopressin is generally well-tolerated in most patients. There are a few instances where patients require monitoring for adverse effects of the drug. Patients receiving desmopressin need monitoring for the occurrence of hyponatremia.[23] Symptoms of hyponatremia include nausea, confusion, or altered mental status.[24] As patients age, they should also be continually monitored for declining renal function, as the therapeutic index and clearance of the drug will change according to the renal function. 


There is no known antidote to an overdose of desmopressin. The most worrisome complication to result from an overdose is water intoxication. This condition would result in a delayed loss of consciousness and seizures in some instances. Patients require immediate admission to the intensive care unit to be monitored and have electrolyte correction.[25]

Enhancing Healthcare Team Outcomes

Desmopressin is a relatively safe drug for use, but it still requires the efforts of an interprofessional healthcare team for optimal therapeutic success. This team will include clinicians, specialists, mid-level practitioners, nurses, and pharmacists, coordinating their activities and sharing information to achieve the best patient outcomes. [Level 5] 

Patients receiving desmopressin to treat hemophilia A or von Willebrand disease can remain at risk of bleeding. As such, these patients require an integrated and cohesive team of specialists consisting of the primary care physician, hematologist, and, in some instances, a gynecologist and geneticist. The primary care physician must ensure that the patients are regularly following up with a hematologist or a hemophilia treatment center. In cases of pregnancy, a woman can receive genetic counseling either before becoming pregnant or later on during the pregnancy.[5] Parents with children suffering from these disorders must understand the complications of the disease and the proper administration of the medication in the case of an emergency.



Ozgönenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgraduate medical journal. 2007 Mar:83(977):159-63     [PubMed PMID: 17344569]


Fein S, Herschkowitz S. Low-Dose Desmopressin Nasal Spray and FDA Approval. JAMA. 2017 Sep 19:318(11):1070-1071. doi: 10.1001/jama.2017.11327. Epub     [PubMed PMID: 28975296]


Wiśniewski K, Qi S, Kraus J, Ly B, Srinivasan K, Tariga H, Croston G, La E, Wiśniewska H, Ortiz C, Laporte R, Rivière PJ, Neyer G, Hargrove DM, Schteingart CD. Discovery of Potent, Selective, and Short-Acting Peptidic V(2) Receptor Agonists. Journal of medicinal chemistry. 2019 May 23:62(10):4991-5005. doi: 10.1021/acs.jmedchem.9b00132. Epub 2019 May 7     [PubMed PMID: 31022340]

Level 2 (mid-level) evidence


. Desmopressin (Nocdurna and Noctiva) for nocturnal polyuria. The Medical letter on drugs and therapeutics. 2019 Mar 25:61(1568):46-48     [PubMed PMID: 31022158]

Level 3 (low-level) evidence


Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Konkle BA, Nakaya Fletcher S. Hemophilia A. GeneReviews(®). 1993:():     [PubMed PMID: 20301578]


Di Iorgi N, Morana G, Napoli F, Allegri AE, Rossi A, Maghnie M. Management of diabetes insipidus and adipsia in the child. Best practice & research. Clinical endocrinology & metabolism. 2015 Jun:29(3):415-36. doi: 10.1016/j.beem.2015.04.013. Epub 2015 May 9     [PubMed PMID: 26051300]


Chanson P, Salenave S. Treatment of neurogenic diabetes insipidus. Annales d'endocrinologie. 2011 Dec:72(6):496-9. doi: 10.1016/j.ando.2011.09.001. Epub 2011 Nov 8     [PubMed PMID: 22071315]


Ott M, Forssén B, Werneke U. Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia: a retrospective cohort study. Therapeutic advances in psychopharmacology. 2019:9():2045125319836563. doi: 10.1177/2045125319836563. Epub 2019 Apr 4     [PubMed PMID: 31007893]

Level 2 (mid-level) evidence


Alharfi IM, Stewart TC, Foster J, Morrison GC, Fraser DD. Central diabetes insipidus in pediatric severe traumatic brain injury. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2013 Feb:14(2):203-9. doi: 10.1097/PCC.0b013e31827127b5. Epub     [PubMed PMID: 23314181]

Level 2 (mid-level) evidence


Leroy C, Karrouz W, Douillard C, Do Cao C, Cortet C, Wémeau JL, Vantyghem MC. Diabetes insipidus. Annales d'endocrinologie. 2013 Dec:74(5-6):496-507. doi: 10.1016/j.ando.2013.10.002. Epub 2013 Nov 25     [PubMed PMID: 24286605]


Chanson P, Salenave S. Diabetes insipidus and pregnancy. Annales d'endocrinologie. 2016 Jun:77(2):135-8. doi: 10.1016/j.ando.2016.04.005. Epub 2016 May 9     [PubMed PMID: 27172867]


Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Seminars in thrombosis and hemostasis. 2004 Oct:30(5):579-89     [PubMed PMID: 15497100]


Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. The New England journal of medicine. 1983 Jan 6:308(1):8-12     [PubMed PMID: 6401193]

Level 1 (high-level) evidence


Freitas SDS, Rezende SM, de Oliveira LC, Prezotti ANL, Renni MS, Corsini CA, Amorim MVA, Matosinho CGR, Carvalho MRS, Chaves DG. Genetic variants of VWF gene in type 2 von Willebrand disease. Haemophilia : the official journal of the World Federation of Hemophilia. 2019 Mar:25(2):e78-e85. doi: 10.1111/hae.13714. Epub 2019 Feb 28     [PubMed PMID: 30817071]


Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Goodeve A, James P. von Willebrand Disease. GeneReviews(®). 1993:():     [PubMed PMID: 20301765]


Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, Del Zoppo GJ, Kumar M, Peerschke EI, Stiefel MF, Teitelbaum JS, Wartenberg KE, Zerfoss CL. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine. Critical care medicine. 2016 Dec:44(12):2251-2257     [PubMed PMID: 27858808]


Rafat C, Schortgen F, Gaudry S, Bertrand F, Miguel-Montanes R, Labbé V, Ricard JD, Hajage D, Dreyfuss D. Use of desmopressin acetate in severe hyponatremia in the intensive care unit. Clinical journal of the American Society of Nephrology : CJASN. 2014 Feb:9(2):229-37. doi: 10.2215/CJN.00950113. Epub 2013 Nov 21     [PubMed PMID: 24262506]

Level 2 (mid-level) evidence


Narayen G, Mandal SN. Vasopressin receptor antagonists and their role in clinical medicine. Indian journal of endocrinology and metabolism. 2012 Mar:16(2):183-91. doi: 10.4103/2230-8210.93734. Epub     [PubMed PMID: 22470853]


Mannucci PM, Levi M. Prevention and treatment of major blood loss. The New England journal of medicine. 2007 May 31:356(22):2301-11     [PubMed PMID: 17538089]


Kaminetsky J, Fein S, Dmochowski R, MacDiarmid S, Abrams S, Cheng M, Wein A. Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials. The Journal of urology. 2018 Sep:200(3):604-611. doi: 10.1016/j.juro.2018.04.050. Epub 2018 Apr 12     [PubMed PMID: 29654805]

Level 1 (high-level) evidence


Gasthuys E, Vermeulen A, Croubels S, Millecam J, Schauvliege S, van Bergen T, De Bruyne P, Vande Walle J, Devreese M. Population Pharmacokinetic Modeling of a Desmopressin Oral Lyophilisate in Growing Piglets as a Model for the Pediatric Population. Frontiers in pharmacology. 2018:9():41. doi: 10.3389/fphar.2018.00041. Epub 2018 Jan 31     [PubMed PMID: 29445339]


Lim CC, Siow B, Choo JCJ, Chawla M, Chin YM, Kee T, Lee PH, Foo M, Tan CS. Desmopressin for the prevention of bleeding in percutaneous kidney biopsy: efficacy and hyponatremia. International urology and nephrology. 2019 Jun:51(6):995-1004. doi: 10.1007/s11255-019-02155-9. Epub 2019 Apr 26     [PubMed PMID: 31028561]


Agersø H, Seiding Larsen L, Riis A, Lövgren U, Karlsson MO, Senderovitz T. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. British journal of clinical pharmacology. 2004 Oct:58(4):352-8     [PubMed PMID: 15373927]

Level 1 (high-level) evidence


Shrimanker I, Bhattarai S. Electrolytes. StatPearls. 2023 Jan:():     [PubMed PMID: 31082167]


Segal-Kuperschmit D, Dali-Gotfrid O, Luder A. [Water intoxication following desmopressin overdose]. Harefuah. 1997 Apr 1:132(7):465-7, 527, 526     [PubMed PMID: 9153915]

Level 3 (low-level) evidence